Sök artiklar i SveMed+

Observera: SveMed+ upphör att uppdateras!



Porfyrisykdommer i Norge
Engelsk titel: Porphyrias in Norway Läs online Författare: Mykletun, Mira ; Aarsand, Aasne Karine ; Stöle, Egil ; Villanger, Jörild Haugen ; Tollånes, Mette Christophersen ; Baravelli, Carl ; Sandberg, Sverre Språk: Nor Antal referenser: 26 Dokumenttyp: Artikel UI-nummer: 14057920

Tidskrift

Tidsskrift for Den Norske Laegeforening 2014;134(8)831-5 ISSN 0029-2001 E-ISSN 0807-7096 KIBs bestånd av denna tidskrift Denna tidskrift är expertgranskad (Peer-Reviewed)

Sammanfattning

BACKGROUND Porphyria is an umbrella term for a group of largely hereditary diseases that are due to defective haem synthesis. The diseases have a varied and partly overlapping range of symptoms and presentations. The commonest forms of porphyria are porphyria cutanea tarda, acute intermittent porphyria and erythropoietic protoporphyria. The purpose of this study was to provide an overview of the prevalence and pathological manifestations of porphyrias in Norway. MATERIAL AND METHOD Information on all patients registered with the Norwegian Porphyria Centre (NAPOS) up to 2012 was used to estimate the prevalence and incidence of porphyrias in Norway. Figures on symptoms, precipitating factors and follow-up routines were obtained from the Norwegian Porphyria Registry, which includes 70 % of Norwegians registered with NAPOS as having porphyria. RESULTS The prevalence of porphyria cutanea tarda was approximately 10 : 100 000 and that of acute intermittent porphyria approximately 4 : 100 000. The total incidence of all porphyrias was approximately 0.5 - 1 : 100 000 per year. Diagnostic delay, i.e. the time passing between the onset of symptoms and diagnosis, varied from 1 - 17 years depending on the type of porphyria. There was wide variation in the frequency with which patients with the various types of porphyria went for medical check-ups. INTERPRETATION The prevalence of acute intermittent porphyria and porphyria cutanea tarda appears to be higher in Norway than in most other countries. Data from the Norwegian Porphyria Registry make it possible to demonstrate differences in treatment and follow-up of porphyria patients and may be used to initiate necessary measures.